Hepatitis Forums
Hepatitis C Main Forums => Hepatitis C Research News & Studies => Topic started by: Hep Editors on April 27, 2015, 08:38:27 pm
-
Six weeks of Gilead Sciences’ triple regimen of a fixed-dose combination of Sovaldi (sofosbuvir) and new drugs GS-5816 plus GS-9857 cured 93% of easier-to-treat (read: non-cirrhotic, treatment naive) people with genotype 1 of hepatitis C virus.
It was less successful among those with cirrhosis and especially people who had failed a previous treatment.
For more info, click here: http://www.hepmag.com/articles/5816_9857_Gilead_2501_27122.shtml